← All indications
Cross Infection
Any infection which a patient contracts in a health-care institution.
Subtype terms (1)
More specific conditions that are subtypes of Cross Infection in the MeSH hierarchy.
- Healthcare-Associated Pneumonia
47 drugs (39 approved, 8 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (21)
Phase 3 trials (9)
Phase 2 trials (11)
Organizations
Organization Involved with Phase 4 Indications (22)
- Merck
- Pfizer
- Wyeth
- GlaxoSmithKline
- Fondazione Toscana Gabriele Monasterio
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
- University of Pennsylvania
- Mahidol University
- Mashhad University of Medical Sciences
- Monash University
- Siriraj Hospital
- Universidad Autonoma de Madrid
- University of Maryland
- University of Munster
- Babol University of medical scienses
- University of Oxford
- University of Perugia
- Department of Veteran Affairs
- National Health and Medical Research Council, Australia
- B. Braun
- Johnson and Johnson
- Centre for Infectious Disease Research in Zambia (CIDRZ)
Organization Involved with Phase 3 Indications (15)
- Novartis
- Chulalongkorn University
- Federal University of Rio Grande do Sul
- Johns Hopkins University
- Medical University of Warsaw
- Onze Lieve Vrouw Hospital
- University of Seville
- Colombian Neonatal Research Network
- University of Naples Frederico II
- Vanderbilt University
- University of Amsterdam
- University of Strasbourg
- Pontificia Universidad Javeriana
- University of Paris
- Sage Products, Inc.
Organization Involved with Phase 2 Indications (12)
- Agennix
- National Institutes of Health (NIH)
- Canadian Critical Care Trials Group
- Centre Hospitalier Universitaire de Nīmes
- Harvard University
- Queen's University, Belfast
- University of Toronto
- Columbia University
- University of Cincinnati
- Sao Paulo State University
- The Physicians' Services Incorporated Foundation
- São Paulo Research Foundation (FAPESP)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (15)
- Bristol-Myers Squibb
- Inhibitex
- Epicentre
- The Methodist Hospital System
- Bnai Zion Medical Center
- University of Alberta
- Prince of Songkla University
- University of California, Irvine
- University of Lille
- Hospital Corporation of America
- Methodist Cancer Center, Houston, Texas
- China Medical University
- Government of Niger
- The University of Texas, Dallas
- Medecins Sans Frontieres